Fig. 3From: Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulationRegorafenib and panobinostat induce tumor growth inhibition in vivo. Mice xenografted with A, VAESBJ tumors and A204 tumors were treated daily with 30 mg/kg regorafenib p.o.; graph represents means ± SEM of N = 8 to 9 tumors per group. Statistical analysis in both experiments was performed using the nonparametric Mann-Whitney test; p < 0.001 each. B Animals bearing VAESBJ tumors were treated with 8 and 12 mg/kg panobinostat i.p. three times per week; graph represents means ± SEM of N = 11 to 16 tumors per group. Statistical analysis was performed using the nonparametric Kruskal-Wallis test; p < 0.05 for 8 mg/kg and p < 0.0005 for 12 mg/kg. C ERK and AKT activation in tumors harvested after 24 h of a single dose of 8 and 12 mg/kg panobinostat i.p. are shown by Western blotBack to article page